This year, harm reduction service providers from across Europe assessed the state of essential harm reduction services in European cities for the fifth time, with as many as 40 cities responding to our survey in 35 countries. This has been the highest number of respondents filling in the questionnaire in the history of C-EHRN Monitoring.

Data in this report was collected during the spring of 2024. The respondents represent the Correlation – European Harm Reduction Network (C-EHRN) Focal Points (FPs).

The services with the highest reported availability include HIV testing (25/40 FPs, 62.5% reporting ‘great’ extent of availability); HIV treatment (23/40 FPs, 57.5%); and opioid agonist therapy (OAT) (23/40 FPs, 57.5%). Conversely, the lowest availability was observed (in ascending order) in the case of NSP in prison (31/40 FPs, 77.5%, indicating ‘not at all’); naloxone in prison (27/40 FPs, 67.5%); and drug consumption rooms (27/40 FPs, 67.5%). It is also worth mentioning that drug checking and income generation opportunities for people who use drugs both had a relatively high share of ‘not at all’ responses (19 and 11, respectively) and ‘to a small extent’ (11 and 15, respectively), which makes their availability low.